Elekta Xoft is currently being studied for the treatment of multiple types of brain tumors in leading institutions worldwide. Following please find details of ongoing research
Supporting Clinical Research
Elekta Xoft is currently being studied for the treatment of multiple types of brain tumors in leading institutions worldwide. Following please find details of ongoing research:
- Researchers at the European Medical Center (EMC) in Moscow, one of the largest private medical clinics in Russia and an international leader in comprehensive care and oncology, are researching Xoft brain IORT for the treatment of recurrent glioblastoma multiforme (GBM). In a matched pair study, a total of 30 patients were treated with recurrent GBM between August 2016 and June 2019. All patients underwent maximal safe resection; patients were divided into IORT and EBRT groups. The IORT group (A) was treated with a single fraction of radiation immediately following surgical resection, without chemotherapy or temozolomide following surgery. The comparison group (B) was treated with routine postoperative adjuvant chemotherapy +/- concomitant or sequential EBRT.
- According to positive clinical research submitted to the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program in May 2020 by Nidal Salim, MD, radiation oncologist and head of the radiotherapy center at the EMC, median overall survival (OS) was 27 months in the IORT group, versus 21 months in the EBRT group. The local progression free survival (locPFS) range for the IORT group was between 3.5 to 39 months, versus 2 to 10 months in the EBRT group. As of December 2019, 8 patients were alive out of the IORT group, whereas none of the patients of the EBRT group survived. This research will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.
- Positive preliminary clinical data on Xoft IORT were presented at the European Association of Neurosurgical Societies (EANS) Congress in Dublin, Ireland in September 2019 by Alexey Gaytan, MD, PhD, neurosurgeon at the EMC. Median overall survival (OS) in the IORT group was 24 months; OS for the EBRT group was 21 months. As of September 2019, nine patients were still alive from the IORT group, whereas none of the patients from the EBRT group survived.
- Researchers at the James Graham Brown Cancer Center at the University of Louisville are currently conducting a clinical trial on IORT for patients with large brain metastases treated with neurological resection with Elekta Xoft. In February 2020, the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using Elekta Xoft at this facility.4
- A retrospective analysis published in World Neurosurgery by Alexey Krivoshapkin, MD, PhD, et al. examined the repeat resection and the various methods of IORT for the treatment of malignant brain gliomas (MBGs), including high-energy linear accelerators and modern, integrated brachytherapy solutions using solid and balloon applicators.5 The findings from this review showed IORT with balloon applicators to be particularly promising.